| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci |
| Active, not recruiting | 2 | 220 | RoW | humanized anti-PD-1 monoclonal antibody Toripalimab, JS001, TAB001, high-dose recombinant interferon a-2B, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Intron A | Shanghai Junshi Bioscience Co., Ltd. | Mucosal Melanoma | 04/22 | 04/25 | | |
NCT04524884: Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study |
|
|
| Not yet recruiting | 2 | 10 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Fudan University | Thyroid Cancer | 04/22 | 09/22 | | |
ChiCTR2000031692: A prospective phase II clinical study of TACE combined with triplezumab and metronochemotherapy in the treatment of advanced hepatocellular carcinoma (HCC) |
|
|
| Not yet recruiting | 2 | 30 | China | TACE combined with triplezumab and metronochemotherapy | The Seventh Affiliated Hospital of Sun Yat-Sen University ; The Seventh Affiliated Hospital of Sun Yat-Sen University, Self-raised funds | Hepatocellular carcinoma (HCC) | | | | |
NCT04338282: Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 20 | NA | toripalimab, anti-PD-1-antibody | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma, Nasal Type | 05/22 | 05/23 | | |
NCT03941795: Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma |
|
|
| Recruiting | 2 | 99 | RoW | JS001(Toripalimab Injection), Axitinib 1 MG [Inlyta], JS001 and Axitinib | Peking University Cancer Hospital & Institute | Advanced Mucosal Melanoma | 06/22 | 12/22 | | |
ChiCTR2000033506: A phase II trial of TP and Toripalimab neoadjuvant chemotherapy followed by Toripalimab concurrent radiotherapy for patients with local advanced laryngeal/hypopharyngeal carcinoma |
|
|
| Recruiting | 2 | 43 | China | TP and Toripalimab neoadjuvant chemotherapy followed by Toripalimab concurrent radiotherapy | Sun Yat-Sen University Cancer Center ; Level of the institution：, Shanghai Junshi Biosciences Co., Ltd. | Laryngeal carcinoma /hypopharyngeal carcinoma | | | | |
NCT04992988: Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial |
|
|
| Recruiting | 2 | 40 | RoW | Toripalimab | Cancer Hospital of Guangxi Medical University | Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma | 06/22 | 06/22 | | |
NCT04825938: Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms |
|
|
| Not yet recruiting | 2 | 15 | RoW | Toripalimab , Carboplatin, Nab-paclitaxel | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Salivary Gland Malignant Neoplasms, Salivary Gland Tumors | 06/22 | 06/27 | | |
NCT04891016: Toripalimab Plus FLOT in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 60 | RoW | FLOT combined with toripalimab, FLOT plus toripalimab | Henan Cancer Hospital | Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma | 12/25 | 12/28 | | |
MTAM, NCT04472806: Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma |
|
|
| Recruiting | 2 | 31 | RoW | Toripalimab, JS001, chemotherapy in combination with Endostar | Fudan University, Zhejiang Cancer Hospital, Fujian Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Mucosal Melanoma | 06/22 | 06/23 | | |
NCT04250948: Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 108 | RoW | JS001, PD-1 antibody, Oxaliplatin, S1, Capecitabine, XELODA | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Locally Advanced Solid Tumor | 06/22 | 10/24 | | |
NCT06156891: PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC |
|
|
| Recruiting | 2 | 60 | RoW | Toxicities reduced treatment, Conventional treatment | Fudan University | Oropharyngeal Cancer | 07/25 | 07/25 | | |
TOGATHER, NCT04144608: Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer |
|
|
| Completed | 2 | 40 | RoW | Toripalimab combination with platinum-containing dual-drug chemotherapy | Yongchang Zhang | Advanced Non Small Cell Lung Cancer | 06/22 | 07/23 | | |
ChiCTR1900022491: A phase 2 study for PD-1 antibody JS001 in Participants With Microsatellite Instability-High (MSI-H) advanced or recurrent colorectal cancer |
|
|
| Not yet recruiting | 2 | 40 | | JS001 | Fudan University Zhongshan Hospital; Fudan University Zhongshan Hospital, Shanghai Tongshu Biotech Co., Ltd；Shanghai Junshi biosciences Co., Ltd | Colorectal cancer | | | | |
ChiCTR2100043981: Toripalimab Combined with Concurrent Chemoradiotherapy in Stage IV Hypopharyngeal Carcinoma without Distant Metastasis |
|
|
| Recruiting | 2 | 76 | China | Toripalimab combined with concurrent chemotherapy ;concurrent chemotherapy | National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC ; Level of the institution：, Suzhou Zhonghe Biomedical Technology Co., Ltd | hypopharyngeal cancer | | | | |
NCT04627363: HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama |
|
|
| Not yet recruiting | 2 | 30 | NA | Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma, Bevacizumab, Liver Neoplasms, Toripalimab, Oxaliplatin | 06/22 | 06/23 | | |
NCT04398056: Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 22 | RoW | Chemotherapy plus radiotherapy and Toripalimab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 07/22 | 07/24 | | |
| Recruiting | 2 | 30 | RoW | TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®) | Peking University Cancer Hospital & Institute | Mucosal Melanoma | 07/22 | 12/22 | | |
NCT03946943: Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma |
|
|
| Not yet recruiting | 2 | 25 | RoW | Anlotinib, Toripalimab, Blood Draw, Phlebotomy, Tumor Specimen Collection, Core-Needle Biopsy | Di Wu | Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | 07/22 | 07/23 | | |
ChiCTR2000039371: Evaluating the efficacy and safety of Teriprizumab injection (JS001) combined with lenvatinib as first-line treatment in patients with Advanced Hepatocellular Carcinoma: a single-arm, open-label clinical trial. |
|
|
| Recruiting | 2 | 30 | China | Teriprizumab injection + Lenvatinib | Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guangxi Medical University ; Affiliated Cancer Hospital of Guangxi Medical University, Shanghai Junshi Biomedical Technology Co., Ltd. | Hepatocellular Carcinoma | | | | |
NCT04888403: Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Toripalimab+Nedaplatin+Albumin Paclitaxel | The First Affiliated Hospital of Zhengzhou University | Locally Advanced Esophageal Squamous Cell Carcinoma | 07/22 | 07/22 | | |
| Not yet recruiting | 2 | 14 | RoW | Surufatinib(HMPL-012), Toripalimab | Fujian Cancer Hospital | Nasopharyngeal Carcinoma | 08/22 | 08/23 | | |
IMPORT, NCT04523883: Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The Study |
|
|
| Recruiting | 2 | 316 | RoW | postoperative radiotherapy, JS001, Toripalimab | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Fudan University, Eye & ENT Hospital of Fudan University, Tianjin Medical University Cancer Institute and Hospital, First Affiliated Hospital of Fujian Medical University, Guizhou Provincial People's Hospital, Central South University | Head and Neck Squamous Cell Carcinoma | 08/22 | 08/24 | | |
NCT04278222: Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE) |
|
|
| Recruiting | 2 | 30 | RoW | Anlotinib Plus Toripalimab | Shanghai Changzheng Hospital | Gastric Cancer, Gastro-oesophageal Junction Cancer, Immunotherapy, Anlotinib, Toripalimab | 08/22 | 08/22 | | |
NeoTENNIS, NCT04418154: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 70 | RoW | epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel, Toripalimab | Fudan University | Triple Negative Breast Cancer | 09/22 | 12/25 | | |
NCT04119622: Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, oxaliplatin, capecitabine | Aiping Zhou | Gastric Cancer Stage II, Gastric Cancer Stage III | 09/22 | 10/24 | | |
NCT04099589: Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma |
|
|
| Recruiting | 2 | 64 | RoW | Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University First Hospital, China-Japan Friendship Hospital | Upper Tract Urinary Carcinoma, Muscle-invasive Bladder Cancer | 10/22 | 10/22 | | |
NCT04880811: Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification |
|
|
| Not yet recruiting | 2 | 43 | RoW | Afatinib, Toripalimab | Peking University | Esophageal Squamous Cell Carcinoma | 10/22 | 05/23 | | |
ChiCTR2000039175: Clinical Study of Toripalimab with Anlotinib for Patients With Recurrent Glioblastoma |
|
|
| Recruiting | 2 | 50 | China | Toripalimab and Anlotinib | Tangdu Hospital, Fourth Military Medical University ; Tangdu Hospital, cost of scientific research | recurrent glioblastoma | | | | |
NCT05350943: HAIC Combined With Toripalimab and Donafenib for Advanced BTC |
|
|
| Enrolling by invitation | 2 | 70 | RoW | HAIC, Gemcitabine, Oxaliplatin, Toripalimab, Donafenib | Lu Wang, MD, PhD | Biliary Tract Adenocarcinoma | 11/22 | 11/23 | | |
NCT05522985: Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 122 | RoW | Triprilimab combined with TP | Tianjin Medical University Cancer Institute and Hospital | Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy | 11/22 | 11/24 | | |
NCT04613804: Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy |
|
|
| Not yet recruiting | 2 | 30 | RoW | Toripalimab Injection, PD-1 inhibitor | Fujian Cancer Hospital | NSCLC Stage IV | 11/22 | 11/23 | | |
| Completed | 2 | 50 | RoW | GS+Toripalimab | Shanghai Zhongshan Hospital, Shanghai Junshi Bioscience Co., Ltd., OrigiMed | Biliary Tract Cancer | 12/21 | 03/22 | | |
NCT04973904: Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer |
|
|
| Not yet recruiting | 2 | 35 | RoW | Toripalimab, Paclitaxel, Cisplatin, Bevacizumab | Peking Union Medical College Hospital | Cervical Cancer | 12/22 | 12/23 | | |
NCT04443036: Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma |
|
|
| Recruiting | 2 | 44 | RoW | Albumin-Bound Paclitaxel, Paclitaxel (albumin-bound), Paclitaxel for injection(Albumin Bound), Toripalimab | China Medical University, China | Gastric Carcinoma | 12/22 | 12/23 | | |
| Not yet recruiting | 2 | 40 | China | 特瑞普利单抗联合全脑放疗 | Department of Radiation Oncology, Third Affiliated Hospital of Soochow University ; Third Affiliated Hospital of Soochow University, Self funding | Malignant neoplasm metastasis in brain | | | | |
NCC2167, NCT04389073: Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine |
|
|
| Recruiting | 2 | 138 | RoW | Vinorelbine 40mg, Toripalimab 240mg, JS001, Bevacizumab 5 mg/kg, Cyclophosphamide 50 mg, Capecitabine 500Mg Oral Tablet, Cisplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Huanxing Cancer Hospital | Metastatic Breast Cancer | 12/22 | 12/23 | | |
NCT04363255: First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC |
|
|
| Not yet recruiting | 2 | 20 | RoW | Etoposide Injection, Etoposide, Carboplatin Injection, Carboplatin, Cisplatin injection, Cisplatin, Toripalimab, JS001, Anlotinib hydrochloride, Anlotinib | Taizhou Hospital | Small Cell Lung Carcinoma | 12/22 | 03/23 | | |
NCT04425824: Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 20 | RoW | Toripalimab combine with Rituximab, JS001 combine with rituxan | Chinese Academy of Medical Sciences | Diffuse Large B-cell Lymphoma, Rituximab, Toripalimab | 12/22 | 12/22 | | |
NCT04563975: Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 54 | RoW | Toripalimab, JS001, Docetaxel, Taxotere, nab-paclitaxel, AI YUE | Tao Zhang | Gastric Cancer Stage IV | 12/22 | 05/23 | | |
NCT04238169: Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC |
|
|
| Completed | 2 | 60 | RoW | Bevacizumab, Toripalimab, SBRT | Xinqiao Hospital of Chongqing | Non-Small-Cell Lung Cancer Stage IV | 12/22 | 12/23 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05084677: Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer |
|
|
| Recruiting | 2 | 96 | RoW | Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancer | 12/22 | 12/24 | | |
NCT05453383: Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib |
|
|
| Recruiting | 2 | 30 | RoW | Anlotinib;Toripalimab, AL3818;JS001 | Shen Feng | Hepatocellular Cancer | 12/22 | 12/22 | | |
ATNPC, NCT04718701: Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2 | 53 | RoW | Anlotinib+Toripalimab+Nab-paclitaxel, combination therapy | The First Affiliated Hospital with Nanjing Medical University | Pancreatic Neoplasm, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | 02/23 | 02/23 | | |
NCT06241105: Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 69 | RoW | Lenvatinib+Toripalimab. | Peking Union Medical College Hospital, The Second Affiliated Hospital of Dalian Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recurrent Ovarian Carcinoma | 12/24 | 12/25 | | |
2019-012-00CH1, NCT04169672: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 2 | 248 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Hutchison Medipharma Limited | Advanced Solid Tumors | 02/23 | 02/23 | | |
NCT04118855: Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma |
|
|
| Completed | 2 | 20 | RoW | Toripalimab, anti-PD-1 monoclonal antibody, Axitinib | RenJi Hospital | Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma | 02/23 | 03/23 | | |
NCT04405622: Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. |
|
|
| Active, not recruiting | 2 | 21 | RoW | Toripalimab plus gemcitabine | Sun Yat-sen University | Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy | 03/23 | 05/23 | | |
NCT05274438: Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut |
|
|
| Recruiting | 2 | 37 | RoW | JS001+Imatinib mesylate | Beijing Cancer Hospital | Advanced Melanoma | 03/23 | 04/23 | | |
NCT05147844: Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Toripalimab, JS001 | Xinqiao Hospital of Chongqing, Southwest Hospital, China, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma | 12/25 | 03/26 | | |
NCT04421469: Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC |
|
|
| Not yet recruiting | 2 | 39 | RoW | Triprilimab(JS001) | Fujian Cancer Hospital, Zhejiang Cancer Hospital, Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 04/23 | 06/23 | | |
NCT05030246: Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 72 | RoW | Surufatinib/Toripalimab, HMPL-012/JS001 | Peking University | Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer | 04/23 | 07/23 | | |
NCT05003037: Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 106 | RoW | Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin | Li Zhang, MD | Carcinoma, Non-Small-Cell Lung | 04/23 | 04/25 | | |
GIHSYSU-14, NCT03926338: Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 112 | RoW | Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months, Toripalimab, Celecoxib, Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months, Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months, Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months | Sun Yat-sen University | Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy | 04/27 | 04/30 | | |
NCT04553939: Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Toripalimab, Gemcitabine | Henan Cancer Hospital | Urothelial Carcinoma, Bladder Cancer | 05/23 | 12/23 | | |
NCT05448183: An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 45 | RoW | Toripalimab, Gemcitabine,Oxaliplatin | Xuhua Duan | Extrahepatic Cholangiocarcinoma | 05/23 | 05/24 | | |
NCT04217954: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC |
|
|
| Completed | 2 | 32 | RoW | OXA, 5-FU and bevacizumab plus Toripalimab, FOLFOX | Peking University | Advanced Biliary Tract Cancer | 05/23 | 06/23 | | |
Renaissance, NCT04606303: A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. |
|
|
| Enrolling by invitation | 2 | 100 | RoW | Toripalimab combination with platinum-containing dual-drug chemotherapy. | Peking University Cancer Hospital & Institute | Locally Advanced NSCLC | 05/23 | 05/24 | | |
ChiCTR2100046726: A multi-center, open-label, randomized controlled phase II clinical trial of Toripalimab combined with chemoradiotherapy in newly diagnosed locally advanced laryngopharyngeal carcinoma |
|
|
| Recruiting | 2 | 100 | China | TP (Docetaxel + Cisplatin) combined with teriprizumab induction chemotherapy ;Concurrent chemoradiation | Sichuan Cancer Hopspital/Institute ; Sichuan Cancer Hopspital/Institute, The toripalimab is provide by drug companies | laryngopharyngeal carcinoma | | | | |
ChiCTR2100046715: A single-arm, prospective, open-label, phase II clinical trial of toripalimab in combination with induction chemotherapy and concurrent chemoradiation as first-line treatment for advanced/metastatic esophageal carcinoma |
|
|
| Recruiting | 2 | 30 | China | toripalimab in combination with induction chemotherapy and concurrent chemoradiation | Sichuan Cancer Hospital & Institute ; Sichuan Cancer Hospital & Institute, Shanghai Junshi Bioscience Co., Ltd. | Esophagus cancer | | | | |
ChiCTR2000039739: Phase II Study of Thermal Ablation Followed by Toripalimab in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 130 | | Toriplimab is administrated 3 mg/kg intravenously every 3 weeks continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends. ;One to three lesions were completely ablated under the guidance of CT or ultrasound, and toriplimab therapy was started on the third day after ablation (the dose was 3mg / kg, once every three weeks). | Xiangya Hospital, Central South University; Xiangya Hospital, Central South University, Shanghai Junshi Biosciences Co., Ltd. | Hepatocellular carcinoma | | | | |
NCT05356351: An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | RC48- ADC, Triplizumab | Tianjin Medical University Cancer Institute and Hospital, Xiangya Hospital of Central South University, First Affiliated Hospital Xi'an Jiaotong University, The Southwest Hospital of AMU, Tongji Hospital, Chongqing University Cancer Hospital, Hunan Cancer Hospital, Xijing Hospital of Air Force Military Medical University | Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance | 07/23 | 07/27 | | |
NCT06354231: DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC |
|
|
| Recruiting | 2 | 20 | RoW | DV, RC48, Toripalimab, JS001, Laser surgery | Fudan University | Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney | 12/26 | 12/26 | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
| Recruiting | 2 | 200 | RoW | Toripalimab Combined With CAV/IE chemotherapy, CAV/IE alternate chemotherapy | Sun Yat-sen University | Soft Tissue Sarcoma | 01/25 | 06/26 | | |
NCT05485909: Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM |
|
|
| Recruiting | 2 | 32 | RoW | Radiofrequency ablation, Regorafenib and Toripalimab Combination | Sun Yat-sen University | Colorectal Cancer Liver Metastases | 07/23 | 06/24 | | |
NCT05240404: Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma |
|
|
| Recruiting | 2 | 116 | RoW | Toripalimab, Immunotherapy, Thermal ablation, Local treatment | Xiangya Hospital of Central South University | Hepatocellular Carcinoma | 07/23 | 07/24 | | |
NCT04908566: Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 124 | RoW | PD-1 antibody combined with FOLFIRINOX regimen, PD-1 antibody combined with SOX program | Tianjin Medical University Cancer Institute and Hospital | Locally Advanced Gastric Adenocarcinoma | 08/23 | 08/28 | | |
TORAL, NCT04996758: Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy |
|
|
| Active, not recruiting | 2 | 40 | RoW | Toripalimab and Anlotinib | Sun Yat-sen University | Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma | 09/23 | 10/26 | | |
NCT05749575: Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer. |
|
|
| Recruiting | 2 | 28 | RoW | Chidamide Plus Toripalimab Plus Paclitaxel | Sun Yat-sen University | Breast Cancer | 08/23 | 08/24 | | |
NCT05055583: Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab in Combination With Platinum-based Chemotherapy, Toripalimab Injection, JS001, Teruipuli Dankang, TuoYI, Surgical treatment stage, Adjuvant treatment stage | Tang-Du Hospital | NSCLC Stage IV, Oligometastasis | 08/23 | 12/23 | | |
NCT04191343: Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen |
|
|
| Recruiting | 2 | 20 | RoW | Toripalimab injection combined with GEMOX | Zhejiang Cancer Hospital | Advanced Biliary Tract Tumors | 09/23 | 06/24 | | |
IRB-2019-155, NCT04190745: Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study |
|
|
| Recruiting | 2 | 116 | RoW | Toripalimab+Apatinib mesylate, paclitaxel | Zhejiang Cancer Hospital | Gastric Adenocarcinoma | 09/23 | 06/24 | | |
NCT05493332: HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC |
|
|
| Not yet recruiting | 2 | 93 | NA | HAIC(FOLFOX), Hepatic Artery Infusion Chemotherapy, FOLFOX, Oxaliplatin, Leucovorin, Fluorouracil, Toripalimab, Donafenib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hepatocellular Carcinoma | 09/23 | 09/24 | | |
NCT06208826: A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy |
|
|
| Recruiting | 2 | 268 | RoW | Toripalimab, Radiation Therapy, Cisplatin | Tianjin Medical University Cancer Institute and Hospital | Head and Neck Cancer | 09/26 | 09/28 | | |
NCT04459663: JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. |
|
|
| Not yet recruiting | 2 | 50 | RoW | Toripalimab injection combine with Axitinib | Li Zhang, MD | Non-small Cell Lung Cancer | 09/23 | 12/23 | | |
ChiCTR2000039155: A Phase II Study of Toripalimab in Combination with Paclitaxel and Carboplatin in Treatment-Naive Advanced Thymic Carcinoma |
|
|
| Recruiting | 2 | 20 | China | Toripalimab combined with paclitaxel and carboplatin | National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ; Cancer Hospital Chinese Academy of Medical Sciences, N/A | Thymic carcinoma | | | | |
ChestMate-001, NCT04667793: Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor |
|
|
| Recruiting | 2 | 15 | RoW | Toripalimab + Chemotherapy | Shanghai Pulmonary Hospital, Shanghai, China | Thymic Epithelial Tumor | 09/23 | 04/24 | | |
NCT05060471: PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients |
|
|
| Enrolling by invitation | 2 | 27 | RoW | Toripalimab, radiation | Sun Yat-sen University | Anal Canal Cancer, Anal Squamous Cell Carcinoma, Anal Cancer, Anal Canal Cancer Stage I, Anal Canal Cancer Stage II, Anal Canal Cancer Stage III | 04/24 | 06/24 | | |
PNACGEC, NCT05033392: PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer |
|
|
| Recruiting | 2 | 62 | RoW | Toripalimab Injection, JS001 | Wan He | Stomach Neoplasms | 09/23 | 09/24 | | |
QLMM-01, NCT05087602: Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma |
|
|
| Not yet recruiting | 2 | 29 | RoW | Toripalimab and Anlotinib | Qilu Hospital of Shandong University | Locally Advanced or Metastatic Acral Malignant Melanoma | 09/23 | 10/23 | | |
TORCH, NCT04518280: Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 130 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Xeloda, Oxaliplatin, Short-course radiotherapy | Fudan University | Locally Advanced Rectal Cancer | 10/23 | 12/25 | | |
ChiCTR2100049819: A Phase II Study of Toripalimab plus Re-irradiation with stereotactic body radiotherapy (SBRT) for Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): The RePASS-II study |
|
|
| Not yet recruiting | 2 | 20 | | SBRT+PD-1 antibody | Shanghai Ninth People's Hospital; Shanghai Ninth People's Hospital, None | head and neck cancer | | | | |
NCT04861584: Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects |
|
|
| Recruiting | 2 | 41 | RoW | Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin, Toripalimab | Zhujiang Hospital | Urinary Bladder Cancer | 10/23 | 04/25 | | |
NCT06127303: Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 54 | RoW | Toripalimab, Immunotherapy, Cryoablation | Shanghai Chest Hospital | Non-small Cell Lung Cancer | 11/25 | 11/26 | | |
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. |
|
|
| Recruiting | 2 | 90 | RoW | Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001 | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 12/27 | | |
NCT06178159: DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Disitamab Vedotin Injection, DV,RC48-ADC, Pertuzumab Injection, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Cancer | 12/24 | 06/25 | | |
NCT03930498: Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 68 | RoW | PD-1 blocking antibody, JS001, Chemotherapy, IMRT | Sun Yat-sen University | Recurrent Nasopharyngeal Carcinoma | 12/23 | 12/25 | | |
NCT04804696: Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | Toripalimab, JS001, TAB001, Paclitaxel, Cisplatin | Peking University | Esophageal Squamous Cell Cancer | 12/23 | 12/24 | | |
ChiCTR2100044790: A Clinical Study of the Effcacy and Safety of Donafenib Combined with Toripalimab in the Second-Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 61 | China | Donafenib Combined with Toripalimab; Donafenib Combined with Toripalimab | Chinese PLA General Hospital ; Chinese PLA General Hospital, self funded | SCLC | | | | |
NCT04807140: Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) |
|
|
| Recruiting | 2 | 57 | RoW | Toripalimab, nab-paclitaxel, carboplatin, Toripalimab, Surgical resection | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Head and Neck Squamous Cell Carcinoma | 12/23 | 01/27 | | |
NCT05229315: PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 45 | RoW | Toripalimab, Programmed cell death protein 1(PD-1)；Immune checkpoint inhibitors（ICIs), Intensity modulated radiotherapy | XIANG YANQUN | Nasopharyngeal Carcinoma, T2-3N0 or T1-2N1, EBV-DNA≤4000 Copy/ml | 12/23 | 12/23 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
GASTO-10107, NCT06281886: Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 170 | RoW | Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy, Apatinib, Capecitabine, Chemotherapy concurrently with radiotherapy | Sun Yat-sen University | Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity | 12/26 | 12/26 | | |
NCT05979740: RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC |
|
|
| Recruiting | 2 | 6 | RoW | Disitamab Vedotin and Toripalimab, RC48, JS001 | RenJi Hospital | Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy, PD-1, Antibody-drug Conjugates | 12/23 | 02/24 | | |
NCT04135690: HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial |
|
|
| Recruiting | 2 | 60 | RoW | Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib, systemic treatment | Sun Yat-sen University | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
| Recruiting | 2 | 74 | RoW | chidamide and toripalimab | Sun Yat-sen University | Sarcoma | 12/23 | 12/24 | | |
NICE, NCT04744649: Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial |
|
|
| Recruiting | 2 | 110 | RoW | XELOX or SOX, Control group, JS001+XELOX or SOX, Experimental group and Exploratory group | Nanfang Hospital of Southern Medical University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Stomach Neoplasm | 12/23 | 12/24 | | |
HIFU, NCT05491694: To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After Induction in the Treatment of Early Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab, Epirubicin, High Intensity Focused Ultrasoun, Cyclophosphamide, Carboplatin, Nab-paclitaxel | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer, TNBC - Triple-Negative Breast Cancer | 12/23 | 12/24 | | |